Overall, the inclusion criteria varied among the studies, which may be the main reason why the pooled incidences of AEs were not consistent with those in the IMbarve150 trial; however, the combination therapy was still well tolerated compared with sorafenib or lenvatinib [41, 42], and the toxicities maintained consistency with those of each agent: the most common AEs for atezolizumab were increased AST, ALT, and bilirubin concentrations; proteinuria and hypertension were the most common AEs for bevacizumab; and no new additional toxicities were noticed [17]. Here, GPT is linked to hypertensive disorder.